doi: 10.1001/jama.293.11.1338 81
Scientific and Official Sources Coskun and colleagues: early development of LY3298176 as a dual GIP and GLP-1 receptor agonist PubChem: Tirzepatide molecular formula, mass and chemical record European Medicines Agency: Mounjaro public assessment report and Tirzepatide structural description Willard and colleagues: receptor pharmacology of Tirzepatide MHRA: UK authorisation of Mounjaro containing Tirzepatide Mounjaro official product information MHRA: falsified Mounjaro KwikPen warning, February 2026 MHRA: May 2026 seizure involving unlicensed Tirzepatide products Human Medicines Regulations 2012: Regulation 284 on prescription-only medicine advertising MHRA: investigation into public editorial promotion of Mounjaro MHRA guidance on advertising prescription-only medicines MHRA warning concerning illegal online weight-management medicines
Recalls & Warnings December 24, 2013 Muscle Growth Supplement Linked with Liver Failure On December 23, 2013, the FDA advised consumers to immediately stop using muscle growth supplement Mass Destruction (by Blunt Force Nutrition) because it is labeled as containing at least one synthetic anabolic steroid and has been linked to at least one reported case of liver failure
We provided estimated CY 2026 outlier payments for hospitals and CMHCs with claims included in the claims data that we used to model impacts in the Hospital-Specific ImpactsProvider-Specific Data file on the CMS website at
Researchers often compare it with compounds such as tirzepatide and retatrutide to better understand differences in receptor activity, pharmacology, and experimental outcomes
